Friday, July 08, 2022
BioSig Technologies (BSGM)
BioSig Scores a Big Win
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company’s first product, PURE EP(TM) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Purchase agreement announcement. Yesterday, BioSig Technologies announced a purchase and leasing agreement with Kansas City Heart Institute at Overland Park Regional Medical Center. While terms were not disclosed, Kansas City Heart has multiple EP labs that could benefit from the PURE EP signal processing technology.
National master agreement also announced. Concurrent with the Kansas City Heart commercial announcement, BioSig also announced a national purchase agreement. While not named in the release, it is likely the master was signed with HCA Healthcare given that Kansas City Heart Institute is part of the HCA Midwest Heart and Vascular group. One of the largest hospital networks with 175 general and acute hospitals, HCA represents a substantial opportunity moving forward.…
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
